Result of AGM

Physiomics PLC

19 November 2024

 

19 November 2024

Physiomics plc

("Physiomics" or "the Company")

Result of AGM

Physiomics plc (AIM: PYC), a leading mathematical modelling and data science company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce that all resolutions put to shareholders at the Company's annual general meeting, held earlier today at the Company's offices in Oxford, were duly passed. Voting was conducted by a show of hands and inclusive of votes received by the Company by way of proxy.

Details of the proxy voting results are shown in the table below. 

Ordinary Resolutions	Votes For	%	Votes Against	%	Votes Withheld	Votes Total	% of ISC Voted
1. Approval of the accounts	13,702,827	98.48%	210,852	1.52%	5,844	13,919,523	6.8%
2. Re-appointment of Dr Peter Sargent as a Director of the Company	12,408,973	97.73%	287,661	2.27%	1,222,889	13,919,523	6.8%
3. Re-election of Dr Shalabh Kumar as a Director of the Company	12,408,973	97.73%	287,661	2.27%	1,222,889	13,919,523	6.8%
4. Appointment and renumeration of auditor	13,697,496	98.45%	216,183	1.55%	5,844	13,919,523	6.8%
5. Authority to allot shares	13,328,063	95.79%	585,616	4.21%	5,844	13,919,523	6.8%
Special Resolution
6. Disapplication of shareholders' statutory pre-emption rights	12,108,403	87.03%	1,805,276	12.97%	5,844	13,919,523	6.8%

ISC - Issued Share Capital

Enquiries:

Physiomics plc                                                  

Dr Peter Sargent, CEO

[phone]

Hybridan LLP (broker)

Claire Louise Noyce

[phone]

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

[phone]

Notes to Editor

About Physiomics

Physiomics plc combines expertise across Modelling & Simulation, Biostatistics, Data Science and Bioinformatics, together with deep biology expertise, to help biotech and pharma companies streamline their drug development journeys. Our approach is to help derive insight from all relevant and often disparate data in order to de-risk decision making and optimise research design across discovery, pre-clinical and clinical studies. Through use of cutting-edge computational tools, bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 100 commercial projects, with over 125 targets and drugs modelled. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK. 

 

END